16 January 2025
16 January 2025
GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.
Insmed plans to initiate Phase I clinical trials for its INS1201 gene therapy in H1 2025.
While US earnings grew in 2024, revenues in China were hurt by ongoing investigations in the country.
Regenxbio will receive $110m upfront from Nippon Shinyaku and is eligible to get up to $700m in development, regulatory, and sales milestones.
At the JP Morgan Healthcare Conference 2025, Charles River CEO blamed low client spending, loss of a contract and other reasons for lower 2025 projections.
AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira sales drop.
The financing round saw contributions from new and current investors.
Incyte announced plans for four launches in 2025, beginning with its FDA-approved Niktimvo for chronic GvHD.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
